IART Overview

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.

Wall Street analysts forecast IART stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IART is12.33 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Integra Lifesciences Holdings Corp revenue for the last quarter amounts to 434.93M USD, decreased -1.74

Integra Lifesciences Holdings Corp. EPS for the last quarter amounts to -0.02 USD, decreased -108.00

Integra Lifesciences Holdings Corp (IART) has 4427 emplpoyees as of April 21 2026.

Today IART has the market capitalization of 868.54M USD.